antibacterial drugs: world industry and market prospects 2015 2025
TRANSCRIPT
©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
Antibacterial Drugs: World Industry and Market Prospects
2015-2025
www.visiongain.com
Contents
1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Antibacterial Drugs 2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance
3. Antibacterial Drugs: World Market, 2015-2025
3.1 Antibacterials’ Revenues Plateau between 2009 and 2013
3.2 Antibacterial Agents - Market Segmentation
3.3 Antibiotics Market Forecast, 2015-2025: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterials Market, 2015-2025
3.5 Generic Erosion and Prescription Control will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2015-2025
3.7 Pfizer is the Leader in the Antibacterial Drugs Market
3.8 Fragmented Market to Fracture Further
4. Cephalosporins Market Forecast, 2015-2025
4.1 Cephalosporins Market 2013-2014 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2015 and 2025
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between
2015 and 2025
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2015-2025
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition - Forecast 2015-2025
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2015-2025
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue - Forecast 2015-2025
www.visiongain.com
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2015-2025
4.1.10 Flomox - Shionogi’s Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericisation and Safety to Restrict Sales - Forecast 2015-2025
4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation
Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth - Revenue Forecast 2015-2025
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval - Revenue Forecast 2015-2025
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake - Revenue Forecast
2015-2025
4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from CXA-201 to Limit Sales - Forecast 2015-2025
5. Penicillins Market Forecast, 2015-2025 5.1 Generics and Augmentin Dominate the Penicillins Market in 2013 and 2014
5.2 Augmentin to Lose its Dominance over the Coming 10 Years - Market Shares for Penicillin
Drugs, 2015-2025
5.3 Penicillin Antibacterials: Market Forecast 2015-2025
5.4 Drivers and Restraints for the Penicillin Market 2015-2025
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin – Challenges in Some Countries
5.5.2 Stable Revenues in Spite of Generic Competition
www.visiongain.com
5.5.3 Revenue Forecast 2015-2025
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) - Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2015-2025
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues - Forecast 2015-2025
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue - Forecast 2015-2025
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2015-2025
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2015-2025
6. Fluoroquinolone Market Forecast, 2015-2025
6.1 The Fluoroquinolone Market 2013-2014
6.2 Changing Market Share for Fluoroquinolone Antibacterials, 2015-2025
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2015-2025
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2015-2025
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
www.visiongain.com
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2015-2025
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2015-2025
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2010-2013
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2015-2025
6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2015-2025
6.9.2 Cipro Revenue Forecast 2015-2025: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2015-2025
6.11 Delafloxacin
6.11.1 Revenue Forecast 2015-2025
7. Macrolide Market Forecast, 2015-2025 7.1 Macrolide Market in 2013-2014
7.2 Changing Market Share for Macrolides, 2015-2025
7.3 Macrolide Antibacterials: Market Forecast 2015-2025
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
www.visiongain.com
7.5.1 Revenue 2013-2014
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2015-2025
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2015-2025
7.7 Dalacin
7.7.1 Revenue Forecast 2015-2025
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2015-2025
7.9 Solithromycin
7.9.1 Revenue Forecast 2015-2025
8. Carbapenem Market Forecast, 2015-2025
8.1 Carbapenem Market 2013-2014
8.2 Changing Market Share for Carbapenems, 2015-2025
8.3 Carbapenem Market Forecast, 2015-2025
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
www.visiongain.com
8.5.2 Revenue Forecast 2015-2025
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2015-2025
8.7 Invanz
8.7.1 Revenue Forecast 2015-2025
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2015-2025
9. Other Antibiotic Drugs Forecast, 2015-2025 9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2015-2025
9.3 Other Antibacterials: Market Forecast, 2015-2025
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2025
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic
Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2015-2025
www.visiongain.com
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2019, Revenue Forecast 2015-2025
9.7 Tygacil – A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from OtherTherapies Restricts Growth: Revenue Forecast 2015-2025
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2015-2025
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2015-2025
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US - Revenue Forecast 2015-2025
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast
2015-2025
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2015-2025
9.13 Oritavancin – An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2015-
2025
www.visiongain.com
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2015-2025
9.15 Surotomycin –Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2015-2025
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2015-2025
10. The Leading National Markets, 2015-2025
10.1 US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2015-2025
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2014
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets –
High Incidence Rates in the UK, US and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – High
Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads
the Way
10.5 Antibacterial Drug Consumption by Country, 2014
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Some Other National Markets
10.6 The Antibacterials Market in the US
10.6.1 Continued Dominance of the US Market
10.7 The European Union Forms Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2015-2025
www.visiongain.com
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italy Continues to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 Rising Use of Antibacterials Drugs in the UK
10.7.7 Spanish Antibacterials Market to Expand from 2019 to 2025
10.8 Japan – Still the Third Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2015-2025
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2015-2025
10.12 Indian Market to Expand by 50% Over the Forecast Period
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2015-2025
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales - Forecast 2015-2025
11. Antibacterials R&D Pipeline Review, 2015
11.1 Gram-Positive vs. Gram-Negative
11.2 Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Treatment Candidates
11.3.1 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
www.visiongain.com
11.3.2 Tedizolid – More Potent Than Zyvox with Fewer Doses?
11.3.3 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.4 Solithromycin – Fluroketolide with Favourable Side Effect Profile
11.3.5 Eravacycline – Treating Gram-Negative cUTIs and cIAIs
11.3.6 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.7 Cadazolid: Largest PIII C. Difficile Trial
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Avarofloxacin is Reportedly Still Waiting for a Partner
11.4.3 MK-7655 and Invanz – A Novel β-Lactamase Combination
11.4.4 Omadacycline – Another Phase III-Ready Partnership
11.4.5 Radezolid – Apparently on Melinta’s Back-Burner for Now
11.4.6 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.7 Sutezolid – Sequella Looking to Combine TB Treatments
11.4.8 Taksta (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.4.9 TD-1792 – A Russian Antibacterial Medicine
11.4.10 Brilacidin – A Novel Peptide Antibacterial Agent
11.4.11POL7080 – Polyphor and Roche in Multi-Million Dollar Deal
11.4.12 BC-3781- Unique Mechanism of Action at 23S?
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Developments for Cystic Fibrosis
www.visiongain.com
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 - Early Stage mAb to S. Aureus
11.7 Other Classes
11.7.1 AZD0914 – Novel DNA Gyrase Inhibitor
11.7.2 MRX-I – Safer Oral Oxazolidinone to Treat MRSA
11.7.3 GSK2140944 – BTI Class of Antibiotics
11.7.4 Carbavance – to Treat CRE
12. Qualitative Analysis of the Antibacterials Industry and Market, 2015
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting
Antibacterials, their Developers, Producers and Marketers
12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the
Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand will Remain Strong
www.visiongain.com
12.4 High Prevalence of Bacterial Infection Worldwide
12.5 Worldwide Demand for Antibacterials
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic
Fields
12.7 Cutting into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates - Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
www.visiongain.com
12.19.6 Public Finance Pumping Money into Antibacterial Development
13. Research Interviews from Our Survey 13.1 Dr Bruce R. Donald (Duke University), Dr Amy C. Anderson (University of Connecticut),
and Mr. Pablo Gainza-Cirauqui (Duke University)
13.1.1 OSPREY
13.1.2 OSPREY – Specializes in Accurate Negative Design
13.1.3 Technical Challenges in Predicting Mutations
13.1.4 Success Rate - Top Four Predictions Confirmed in vitro
13.1.5 OSPREY Could Potentially Predict Resistance Mutations to Biologics (mAbs)
13.1.6 Further Work: Optimize Antibody for Highest in vivo Efficacy
13.1.7 Anticipate Mutations – Redesign Drugs to Maximize Effective Lifespan
13.2 Professor Dr Helga Rübsamen-Schaeff, AiCuris GmbH & Co. KG
13.2.1 AiCuris GmbH & Co. KG
13.2.2 Antibacterial Market - Driven by Supportive Frameworks and Initiatives
13.2.3 Surveillance Data of CRO in Germany
13.2.4 CPE in Germany - Regional Spread
13.2.5 AIC499 – to Treat Gram-Negative Infections
13.3 Dr Vu Truong, Founder & CSO, Aridis Pharmaceuticals, United States
13.3.1 Opportunities for Antibacterial Monoclonal Antibodies
13.3.2 Positioning Monoclonal Antibacterials in the Clinic
13.3.3 Differentiating Factor for Biological Antibacterials
13.3.4 Hazard Pitfalls in Clinical Development
13.3.5 Trends in Antibacterial Drug Market – Novel Targets Rewarded
13.3.6 The Commercial Hazard of Acute Therapeutics
www.visiongain.com
13.3.7 Progress from Government Incentives, But More to Come on the Manufacturing Side
13.3.8 Bacteriophages, Potentially Innovative Therapeutics
14. Antibacterial Drugs Market to 2025: Conclusions 14.1 Three Blockbuster Antibacterials in 2014, Leading Brands
14.2 The Leading Branded Antibacterial Drugs in 2025
14.3 Signs of Life in the Antibacterial R&D Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development
www.visiongain.com
www.visiongain.com Page 104
Antibacterial Drugs: World Industry and Market Prospects 2015-2025
Pfizer also markets an oral form of the drug, Unasyn Oral. The drug's US patent expired in 1999
and its sustained presence in the market has been due to successful lifecycle management
strategies. Revenue has been falling for many years generating revenue of $0.23bn in 2012. In
2013, Pfizer reported revenue of $0.22bn for Unasyn.
5.7.1 Falling Revenues - Forecast 2015-2025
Revenue for Unasyn has been falling since patents covering the drug expired in 1999. This trend
will continue for the coming 10 years with mid-single digit declines in annual revenue, reaching
$0.19bn in 2019 and $0.14bn in 2025 (Table 5.9 and Figure 5.7). Throughout the forecast period of
2014-2025, revenue will fall with a CAGR of -3.5%.
Table 5.9 Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
2014 2015 2016 2017 2018 2019Unasyn ($bn) 0.21 0.21 0.21 0.21 0.20 0.19
Annual Growth (%) -2.4 3.7 -3.9 -0.2 -3.4 -5.0CAGR (%) -1.8
2020 2021 2022 2023 2024 2025Unasyn ($bn) 0.18 0.16 0.16 0.15 0.14 0.14
Annual Growth (%) -4.8 -9.0 -3.7 -6.9 -6.1 1.5CAGR (%) -4.9
Figure 5.7 Unasyn Forecast: Revenue ($bn), 2015-2025
0.00
0.05
0.10
0.15
0.20
0.25
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Reve
nue
($bn
)
Year
Source: visiongain 2015 – CAGR values for period 2014-2019 and 2019-2025
Source: visiongain 2015
www.visiongain.com Page 123
Antibacterial Drugs: World Industry and Market Prospects 2015-2025
6.8.3 Revenue Forecast 2015-2025
Revenue for Vigamox is expected to peak in 2015 at $0.39bn. However, growth during the year
and beyond will be restrained by increased uptake for Alcon’s other moxifloxacin antibiotic,
Moxeza. Beyond 2020, as well as competition from Moxeza, Vigamox will also compete with
generic competition and subsequent price erosion. Alcon will look to transfer patients onto Moxeza
to replace Vigamox and maintain market share, which will accelerate the decline in revenue for the
former drug. By 2019, revenue will have fallen to $0.31bn (Table 6.11 and Figure 6.7). Revenue is
expected to reach $0.08bn in 2025.
Table 6.11 Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
2014 2015 2016 2017 2018 2019Vigamox ($bn) 0.39 0.39 0.37 0.36 0.34 0.31
Annual Growth (%) 1.0 -2.0 -3.0 -4.0 -4.0 -10.0CAGR (%) -4.6
2020 2021 2022 2023 2024 2025Vigamox ($bn) 0.16 0.12 0.10 0.09 0.08 0.08
Annual Growth (%) -50.0 -25.0 -10.0 -10.0 -10.0 -11.5CAGR (%) -21.1
Figure 6.7 Vigamox Forecast: Revenue ($bn), 2015-2025
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Reve
nue
($bn
)
Year
Source: visiongain 2015 – CAGR values for period 2014-2019 and 2019-2025
Source: visiongain 2015
www.visiongain.com Page 217
Antibacterial Drugs: World Industry and Market Prospects 2015-2025
antibiotics with 13.9 DDD per 1000 inhabitants per day. However, consumption per capita has
risen by 10% over the past decade and visiongain anticipates a greater demand for antibiotics over
the coming 10 years. This increase in demand will be driven by an increase in the average age of
the population and subsequent rise in incidence of urinary tract infections and pneumonia.
Table 10.14 German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
2014 2015 2016 2017 2018 2019Germany ($bn) 1.06 1.06 1.08 1.10 1.12 1.15
Annual Growth (%) -1.0 0.5 1.2 2.5 1.5 2.5CAGR (%) 1.6
2020 2021 2022 2023 2024 2025Germany ($bn) 1.17 1.19 1.22 1.25 1.29 1.32
Annual Growth (%) 2.0 2.0 2.5 2.5 2.9 2.4CAGR (%) 2.4
Figure 10.9 German Antibacterial Drugs Market: Revenue Forecast ($bn), 2015-2025
10.7.6 Rising Use of Antibacterials Drugs in the UK
Though some countries have reported declining prescribing rates for antibiotics in recent years, in
the UK it has risen. Over the last decade, antibacterial consumption within the UK has increased
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Mar
ket s
ize
($bn
)
Year
Source: visiongain 2015 – CAGR values for period 2014-2019 and 2019-2025
Source: visiongain 2015